CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Breast ductal lavage and fiberoptic ductoscopy

This policy governs coverage and medical necessity determinations for breast ductal lavage (including the HALO Breast Pap Test) and fiberoptic ductoscopy for detection, diagnosis, or treatment of breast cancer for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyBreast ductal lavage and fiberoptic ductoscopy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 1, 2001

Next Review DateAug 1, 2025

Key ActionIf billed, use CPT 19499 (Unlisted procedure, breast) and verify member-specific benefits before submission.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance for Medicare Advantage and Commercial

19499Unlisted CPT code to file claims

Jan 2025Last review date

HALOExample device discussed

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Covered when ALL of the following are met:

Coverage stance: Breast ductal lavage is considered not covered for Medicare Advantage plans and not medically necessary for Commercial Products; fiberoptic ductoscopy is considered not covered for Medicare Advantage plans and not medically necessary for Commercial Products for detection, diagnosis, or treatment of breast cancer due to insufficient evidence that these technologies improve health outcomes compared with more established techniques.

Policy statements in source chunks 4 and 5.

Coverage and applicability are determined by the member's specific contract. Please refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to confirm whether breast ductal lavage and fiberoptic ductoscopy are covered, excluded, or considered not medically necessary under that plan.

For Commercial Products, breast ductal lavage is considered not medically necessary because the evidence is insufficient to determine its effects on health outcomes compared with established techniques for acquiring and evaluating breast cytology. Similarly, fiberoptic ductoscopy is considered not medically necessary for detection, diagnosis, or treatment of breast cancer due to insufficient evidence to support its role in patient evaluation and management.

Provider Responsibilities and Billing Guidance

Prior Authorization

Prior authorization — No prior authorization applicable per the policy; verify member-specific coverage.

Step Therapy

Step therapy — No step therapy requirements described in the policy; confirm member-specific benefit documents for any plan-level step therapy rules.

Billing Rule

Billing / Filing Guidance

Filing and benefits note — If billed, use CPT 19499 (Unlisted procedure, breast). Benefits vary by contract; confirm member Benefit Booklet/Evidence of Coverage/Subsciber Agreement for applicable coverage or not medically necessary/not covered determinations.

19499 Unlisted procedure, breast

Denial Risk

Coverage / Denial Risk

Coverage denial risk — Claims are subject to denial as not covered or not medically necessary for both Medicare Advantage and Commercial contracts per policy; verify member-specific benefits before performing or billing.

Background and Context

Ductal lavage is a technique that uses a microcatheter to cannulate nipple ducts, flush them with saline, and collect ductal epithelial cells for cytologic analysis; it has been proposed as a nonsurgical "breast Pap smear" for women at increased risk of breast cancer. Fiberoptic ductoscopy involves endoscopic visualization of the ductal epithelium via nipple cannulation and may allow targeted biopsy or intraductal interventions. Both procedures have been investigated for indications such as evaluation of spontaneous nipple discharge and follow-up of atypical cytology, but available evidence is insufficient to demonstrate improved diagnostic accuracy, clinical outcomes, or safety compared with established diagnostic approaches.

Definitions

Ductal lavage — technique description and intended use

TechniqueMicrocatheter is inserted into milk ducts through the nipple orifices; saline is flushed through the catheter to wash out epithelial cells for cytological examination.

Intended useRisk assessment and cytological sampling in women at higher risk for breast cancer (e.g., elevated Gail index, personal history of breast cancer, or BRCA mutation) without mammographic abnormality.

Target specimenBreast ductal epithelial cells harvested from individual milk ducts (each breast has ~6–8 ducts) for cytology.

RationaleDesigned to harvest an increased number of cells compared with nipple aspiration and to sample specific ducts for detection of preinvasive disease confined to ductal/lobular epithelium.

Fiberoptic ductoscopy — definition and capabilities

DefinitionEndoscopic visualization of breast ducts via nipple orifice cannulation using a fiberoptic scope to directly inspect the ductal epithelium.

CapabilitiesAllows direct examination of duct lumen and has been used to evaluate spontaneous nipple discharge, follow-up of atypical cytology, delineation of ductal disease margins, and for potential targeted intraductal biopsy or therapy.

Procedure notesExploration is performed through nipple cannulation to inspect ducts that give rise to symptoms or cytologic abnormalities.

HALO Breast Pap Test — device description (FDA-cleared example)

Device exampleHALO ® Breast Pap Test (Halo Healthcare, Inc.) — an FDA-approved, noninvasive device positioned on the nipple to acquire ductal fluid.

MechanismCollects ductal fluid by applying heat, cyclic compression, and suction to the nipple.

Clinical evidence noteOne small manufacturer-funded study showed noninvasive collection of duct fluid but concluded that well-designed randomized controlled studies are required to determine clinical utility.